ClinicalTrials.gg

TargetBeta

NECTIN4

nectin cell adhesion molecule 4 · also nectin-4, PRR4, LNIR, PVRL4 · V-set domain containing

10 programs in company-led studies act on NECTIN4, from 10 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
enfortumab vedotinruleAstellas Pharmaphase 42010 running–NCIt
notiretatug rezetecanJiangsu HengRui Medicinephase 31414 running–the company's pipeline
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 31313 running–NCIt
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 366 running–NCIt
zelenectide pevedotinruleBicycleTxphase 255 runningBTCNCIt
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 254 running–NCIt
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleAvenzo Therapeuticsphase 211 runningTACSTD2NCIt
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleInnate Pharmaphase 111 running–NCIt
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564ruleRondo Therapeuticsphase 111 runningCD28NCIt
CT-202ruleContext Therapeuticsphase 111 running–the studies' text

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.